HIV-derived lentiviral vectors are efficient vehicula to deliver genes into the brain and hold great promise for future gene therapy of neurodegenerative disorders. However, administration of the current vector preparations in mouse brain was found to induce a systemic immune response to vector proteins and a modest inflammation in the brain. Moreover, serum antibodies from vector-treated animals were capable of partially neutralizing lentiviral vector-mediated transduction in cell culture. To avoid this unexpected immune reaction, we have optimized new vector production and purification protocols. Purification by sucrose gradient ultracentrifugation abolished the immune response, but vector titers also decreased substantially. Lentiviral vector production in the absence of serum in the cell culture medium equally reduced immunogenicity without affecting transduction efficiency. These results have important implications for future clinical use of lentiviral vectors, and for the use of lentiviral vectors to create animal models for neurodegenerative diseases that have an important neuroinflammatory component.
Introduction
Lentiviral vectors (LVs) have the potential to become important delivery vehicles for future gene therapy. The efficacy of LV-mediated gene delivery to the brain has now been demonstrated in several experimental animal models. [1] [2] [3] [4] [5] [6] However, before proceeding to clinical applications, the important issues of biosafety, exogenous control of transgene expression and potential immune response have to be investigated in detail. With regard to the latter aspect, we have previously reported that the current LV preparations, made by ultracentrifugation of filtered supernatant, elicit a humoral response to vector proteins and a transient and modest neuroinflammation in mouse brain. 7 The neuroinflammation was evidenced by a transient decrease in NeuN immunoreactivity after LV transduction. In the present study, we have characterized the nature of the observed immune response in much more detail. We demonstrate that these adverse effects are not due to the vector transduction per se, but rather to specific components in the vector preparation. Taking into account that a strong immune response to components of the culture system has been observed in gene therapeutic trials with profoundly immunodeficient SCID and HIV patients, 8, 9 it is clear that all efforts need to be undertaken to eliminate unnecessary foreign proteins from vector preparations.
Results

Antibodies directed against vector preparations are induced by stereotactic injection of LVs in the brain
We have previously reported the presence of antibodies to vector proteins in the serum of mice after a stereotactic injection with LVs in the brain. 7 To follow the kinetics of production of antivector immunoglobulins (Ig) over time, C57BL mice were injected in the striatum with an LV encoding enhanced green fluorescent protein (eGFP). For each animal, sera were collected at different time points and assayed for the presence of antivector Ig (Figure 1a) . Some of the animals received a second injection of the same vector in the contralateral hemisphere 2 months after the first injection. After 2 weeks, a pronounced boosting effect was observed in the mice that were rechallenged (Figure 1a middle and right panel).
In terms of transgene expression in the brain, there was no significant difference in eGFP expression between the right (first injection) and left (second injection) hemisphere (Figure 1b, c) . In control animals that received only one injection with the same vector batch, eGFP expression levels tended to be higher, but this was not statistically significant.
Next, we determined the neutralizing capacity of serum antibodies in mice killed several days to several months after administration of LVs in the striatum. The transduction efficiency in cell culture of an LV preincubated with different dilutions of the mouse sera was compared to the transduction efficiency of a vector incubated with preimmune mouse serum. Sero-neutralization was evidenced (Figure 2a ). Results were grouped into three categories based on the percentage of neutralization at a serum dilution of 1:32. After a single injection with a GFP-LV, about 35% of the animals (six out of 17) had undetectable to low levels of neutralizing antibodies, corresponding to less than 20% neutralization. About 40% of the mice reached a medium level corresponding to 20-50% neutralization, while the remaining 25% were classified in the strong neutralization category (between 50 and 100% neutralization) (Figure 2c) . After a boost injection, the neutralizing Figure 1 Analysis of immune response to LV proteins and transgene expression after boost. (a) Serum antibodies to LV proteins are upregulated after a second administration of LVs. An analysis by Western blot of the immune response to LV proteins for three individual mice is shown. The mice in the boost experiment were first injected in the left hemisphere, and 2 months later in the right hemisphere. The proteins present in an LV preparation were separated by SDS-PAGE and incubated with sera from mice injected in the striatum with LV encoding eGFP. Blood samples were collected at different time intervals after injection (Pre¼before LV transduction, 2w¼2 weeks, 2 m¼2 months, 2.5 m¼2.5 months, 4 m¼4 months). (b, c) Repeated administration of LVs in the brain does not impair transgene expression. (b) Three serial sections around the injection site and spaced 500 mm apart of a mouse brain after two consecutive injections with an LV encoding eGFP. The brain sections were immunostained with an antibody against eGFP. Scale bar¼1 mm (c) EGFP expression was quantified by stereological measurements of transduced brain volume. The data in the chart represent the average value7s.e. of the mean for four animals per condition. 
Characterization of the immunogenic components in the vector preparation
To identify the components in the LV preparation against which the serum antibodies were directed, we analyzed the antibodies for reactivity with the different types of proteins present in the vector preparation, that is, the HIV proteins composing the vector particle, the VSV-G envelope glycoprotein used to pseudotype the vector, components of the 293T producer cells and proteins present in the fetal calf serum (FCS) added to the culture medium. We made Western blots of different protein preparations and developed them using the immunoreactive sera. The pattern detected after incubation with mouse serum was compared with that obtained with serum from an HIV-1-infected patient (Figure 3a) . The latter serum is known to contain antibodies to HIV-1 viral proteins. An immunoreactive band presumably corresponding to p24 was identified in different mouse sera next to an unidentified band of about 100 kDa. However, it was clear that the major bands in the mouse serum did not correspond to HIV proteins. In contrast, when we compared extracts from the 293T producer cells with LV extracts, there was a striking similarity in the banding pattern, suggesting that most of the serum antibodies were directed against 293T cell components (Figure 3a, b) . Against the proteins derived from FCS, run separately, there was no clear immune response (Figure 3b , first lane). A band of about 70 kDa, which was only detected with the LV extract, corresponded to VSV-G, since the same band was visible after transfection of 293T cells with the pMDG plasmid encoding VSV-G (Figure 3c ). In addition, an unidentified band of about 40 kDa was present only in vector extracts and not in 293T cell extracts ( Figure 3b ).
Immune response to LVs is abolished by sucrose gradient purification
To find out whether the observed immune response and the neuroinflammation were due to LV transduction per se or rather due to some components in the vector preparation, we have purified the LV preparations by sucrose density ultracentrifugation. The p24 values of the sucrose-purified fractions dropped more than 100-fold, while the loss in transducing units/ml was about 50-fold (Table 1) . However, both the transducing units per pg p24 and the transduced brain volume per pg p24 increased, suggesting an enrichment in the proportion of functional viral particles in the sucrosepurified fraction. Moreover, in mice injected with Immune response to lentiviral vectors V Baekelandt et al sucrose-purified LVs, no antivector antibodies were detected ( Figure 4b , middle panel). We have previously reported a transient decrease in NeuN immunoreactivity after LVs transduction in mouse brain. 7 In contrast, there was no loss of NeuN immunoreactivity with sucrosepurified LVs (Figure 5b ).
LV production in the absence of FCS reduces immunogenicity
Sucrose gradient purification is a rather cumbersome procedure. Moreover, it was accompanied by a serious drop in vector yield. To reduce the overall protein content in the vector preparations, we next tried to produce LVs without adding FCS to the 293T cell culture medium. Remarkably, when we compared the different LV preparations by SDS-PAGE and silver staining, there was a huge reduction in total protein content not only in the sucrose-purified preparation but also in the serumfree produced vectors (Figure 4a ). The p24 values of the resulting LV preparations dropped about 10-fold. The transducing titers also decreased, but to a lesser extent (Table 1 ). In contrast, the transducing units per pg p24 were similar, or increased even slightly. The serum-free produced lentiviral vectors transduced mouse brain equally well as the standard vector preparations when we measured the transduced brain volume (Figure 5a ). However, after normalization for p24 content, the serumfree productions were about three-fold better. Interestingly, the NeuN immunoreactivity in the brain 2 weeks after injection of a serum-free produced LV appeared normal (Figure 5b ). In terms of the induction of antibodies to vector proteins, there was a major reduction in total serum antibodies in mice after injection with serum-free produced LVs as compared with standard Figure 4 Reduction of antivector antibody response with sucrose-purified and serum-free LVs. (a) Silver staining of LV preparations reveals a major reduction in total protein content between standard preparations and sucrose-purified or serum-free produced LVs. NL: normal production, SF: serum-free production, Suc: sucrose-purified production, SF þ Suc: serumfree and sucrose-purified production. (b) Analysis by Western blot of the immune response to LV proteins after transduction in the brain with standard LVs, sucrose-purified LVs and serum-free LVs encoding eGFP. LV proteins were separated by SDS-PAGE on a 4-12% polyacrylamide gel, blotted and incubated with sera from individual mice (n¼3 per condition). Immune response to lentiviral vectors V Baekelandt et al vector preparations (Figure 4b , right panel). More specifically, the p24 band was consistently absent when using the purified vector preparations.
To better understand the role of FCS in the observed immune response, we set up an experiment to determine the immunogenicity of vectors that were produced serum-free but to which we added FCS either before concentration, or after concentration but before stereotactic injection in mouse brain. There was no clear induction of total serum antibody response in the conditions where FCS was added to the supernatant after serum-free vector production. Interestingly, the vector yield significantly increased by addition of 10% FCS to the supernatant before centrifugation. Since there was no difference in vector titers between serum-free and normal vectors in the supernatant (data not shown), the observed reduction in transducing titers with the concentrated serum-free vectors (Table 1 ) is due to a less-efficient precipitation in the absence of FCS.
We also examined the neutralization capacity of serum from mice injected with serum-free produced vectors. Out of 20 animals tested, 15 mice (75%) displayed undectable to low seroneutralization, five mice (25%) were in the medium seroneutralization category, while none showed high neutralizing antibody titers ( Figure  2c ).
Discussion
LV-mediated gene transfer in the brain has applications for future gene therapy of neurodegenerative disorders. 7 The technology can also be used to create locoregional transgenic rodents or primates, which can serve as animal models for those diseases. Previously, we reported on the induction of antibodies to vector particles in mouse serum after LV transduction of the brain. Antibodies to the reporter protein (eGFP) were less prominent. In the brain, a local neuroinflammatory response was evidenced by a decrease in NeuN staining. Since the host immune response can have detrimental effects on gene therapy efficiency and safety, 8, 10 we have studied the immune response in more detail and elaborated procedures to reduce the immunogenicity. Since neurodegenerative disorders are known to have an inflammatory component, vector-induced neuroinflammation may jeopardize the validity of the animal models created by local LV transduction. Although we realize that species differences may downplay the direct relevance of our data for human trials, reduction of immunogenicity during preclinical evaluation of LV preparations in mice will also benefit future human trials.
The antivector Ig in more than half of the animals had the capacity to at least partially neutralize vector transduction in a seroneutralization assay in cell culture. A pronounced boosting effect of this immune response was observed when the animals were rechallenged with the same dose of vector. Apparently, the immune response had no significant impact on the transgene expression in the brain. To further characterize the inducing antigens, we ran Western blots using the different proteins present in the LV preparations. LVs are typically pseudotyped with glycoprotein G from the vesicular stomatitis virus (VSV-G). VSV-G-pseudotyped LV are inactivated by human serum complement after systemic administration, 11 suggesting that alternative envelopes may be required for some clinical applications. Although antibodies against the VSV-G protein were visible in the mouse sera, they produced only a weak band. The majority of the antivector antibodies induced appeared to be directed against 293T cell components. Cellular proteins associated with disrupted cells may be present as contaminants in the vector pellets. Alternatively, it has been shown that apart from VSV-G, various plasma membrane proteins from the producer cells are incorporated into the retrovirus envelope. 12 In fact, it is known for a decade that specific cellular antigens outnumber the molecules of the HIV envelope glycoprotein, and that antisera to these cellular components can inhibit HIV infection in cell culture. 13 With respect to the HIV proteins present in the LV, only the antibodies against p24 were consistently observed in the serum of injected mice. Another protein source of potential concern in the LV preparations is the FCS added to the culture medium. Indeed, it has been shown recently that a strong anti-FCS response in an adenosine deaminasedeficient patient after T-cell gene therapy may have negatively influenced the outcome of the gene transfer treatments. 8 In our experiments, only minor reactivity with the FCS proteins was observed.
To circumvent the observed immune reaction after LV transduction of mouse brain, we have optimized new vector production and purification protocols. Purification of the LV preparations by sucrose density ultracentrifugation completely abolished the observed immune response as well as the previously reported transient neuroinflammation in the brain, without reduction of the specific transduction efficiency of the vectors (TU/pg). This suggests that the immunogenicity of a vector preparation may be enhanced by the presence of inactive vector particles, cellular debris, serum proteins, etc. More strikingly, a similar result was obtained by producing the LV in the absence of FCS in the culture medium. This might be explained by the immunogenicity of FCS. FCS has indeed been described to induce T-cell-mediated MHC-independent cytotoxicity in T cells and secretion of cytokines, and a correlation between presence of FCS and a type I hypersensitivity reaction has been reported. 8 However, addition of FCS after vector production but before stereotactic injection did not significantly enhance immunogenicity of the vector preparation. Alternatively, since FCS is known to stimulate cell growth, its presence might increase the amount of cell debris during vector production. The reduced total protein content in the serum-free LV preparations could then be responsible for the reduced immunogenicity (Figure 4a) . We did observe a decrease in p24 values and to a lesser extent in vector titers for the serum-free produced vectors. However, this was mainly due to a less-efficient precipitation during ultracentrifugation in the absence of FCS. We are currently investigating how to increase the efficiency of precipitation in the absence of serum.
A thorough characterization of the immune response to viral vectors is of major importance for future clinical applications. One of the reasons for the interest in LVs for gene therapeutic applications is the apparent absence of immune response in the brain, 4, 5, 14, 15 especially compared to the chronic and acute inflammatory responses Immune response to lentiviral vectors V Baekelandt et al induced by (early generation) adenoviral vectors, even after delivery into the brain. 10, 16, 17 There is little information about the immune response after systemic injection of LVs. It has only been studied in immunedeficient mice, 18, 19 or after a short time period after injection, 20 reportedly to avoid immune reactions against the transgene. The immune response raised after injection of the LVs in the brain may be caused by transient disruption of the blood-brain barrier during surgery. Neither the antibodies against the vector proteins nor the occasionally observed antibodies against eGFP affect transgene expression or readministration in the brain. This is likely due to the fact that the brain is immunologically privileged. However, from our work we can extrapolate that systemic administration of LVs will induce antibodies to LV proteins and the transgene, which may jeopardize multiple systemic administrations. Apart from vector purification, the use of tissuespecific promoters may help, by preventing expression in antigen-presenting cells. 21 Immune responses after administration of other viral vectors such as adenoviral (Ad) or adeno-associated virus (AAV) vectors have been characterized much more in detail than for LVs. An additional complication for the use of Ad and AAV vectors is the possibility of a preexisting immune response or a de novo infection against/ with the wild-type virus. 16, 22, 23 To address the severe immune response elicited by Ad vectors, high-capacity Ad vectors that lack all viral genes have been developed. With these vectors the immune response is apparently absent, 16 although preimmunization still reduced expression levels of the transgene in the brain by about 50%. 23 AAV vectors are next to LVs regarded as most promising vehicles for gene transfer and gene therapy in the CNS. In analogy with our findings, both antibodies to vector and transgene proteins were demonstrated after gene transfer to the brain. The immune response correlated poorly with transgene expression and did not prevent efficient readministration. 24 In conclusion, we have demonstrated that also LVs, even after local administration in the brain, can provoke a systemic immune response. Extensive purification and/or removal of FCS from production media can greatly reduce the immunogenicity. This is of importance for future clinical trials with this type of vector and for using LV technology for disease modelling in animals.
Materials and methods
LV production
Second generation HIV-1-derived vector particles, pseudotyped with the envelope of vesicular stomatitis virus (VSV), were produced by a triple transient transfection of 293T cells in DMEM with 1% FCS. The transfer plasmid used contains a multiple cloning site, the SIN-18 deletion, the woodchuck hepatitis post-transcriptional regulatory element and the cPPT/CTS sequence, as described previously. 7 The vector particles in the supernatant were filtered through a 450 mm filter and then sedimented by ultracentrifugation at 15 000 r.p.m. for 5 h at 41C. The pellets were redissolved in PBS. For in vivo experiments, the vectors were further centrifuged for 1 h at 20 000 r.p.m. and redissolved in PBS, resulting in a final 8000-fold concentration. p24 antigen content was determined using the HIV-1 p24 Core Profile ELISA (NEN Life Science Products, Boston, MA, USA). Titers for vectors encoding the eGFP were determined in CHO cells using FACS analysis. For serum-free LV productions, 1 day before transfection, 293T cells were split and seeded in OPTIMEM medium (Gibco, cat. no. 51985026) containing 2% FCS and 0.1 mM gentamicin. Before transfection with the DNA/PEI complex, the cell medium was changed to OPTIMEM medium containing 0% FCS and 0.1 mM gentamicin. After 1 day, the medium was replaced by fresh OPTIMEM medium, again without FCS. The same medium without FCS was used throughout the harvesting of the LV particles.
Vector purification by sucrose gradient ultracentrifugation
After LV production, the vector pellet was dissolved in 100 ml sterile PBS and added gently on top of a 20-80% sucrose gradient. The vector sucrose gradient was ultracentrifuged at 41C for 18 h at 38 000g (20 000 r.p.m. using Beckman Ultracentrifuge with swinging bucket rotor SW50.1). The first 1.5 ml liquid was discarded. The following 1.5 ml fraction contained the LV particles. To concentrate this fraction and remove the sucrose, the vector particles were pelleted by centrifugation at 41C for 1 h at 26 000g (20 000 r.p.m. using Hereaus Biofuge with rotor 75003331). The vector pellet was dissolved in sterile PBS and stored in aliquots at À701C.
Silver staining of LV preparations
SDS-polyacrylamide gel electrophoresis (PAGE) was performed on 4-20% Novex Tris-Glycine gels (Invitrogen EC60252). The samples were 2-normalized to a concentration of 50 transducing units/ml. After electrophoresis, the gel slab was fixed in 50% methanol and 5% acetic acid in water for 20 min. It was washed for 10 min with 50% methanol in water and additionally for 10 min with water to remove the remaining acid. The gel was sensitized by a 1 min incubation in 0.02% sodium thiosulfate, and then rinsed with two changes of distilled water for 1 min each. After rinsing, the gel was submerged in chilled 0.1% silver nitrate solution and incubated for 20 min at 41C. After incubation, the silver nitrate was discarded, and the gel slab was rinsed twice with water for 1 min and then developed in 0.04% formalin (35% formaldehyde in water) in 2% sodium carbonate with intensive shaking. The development was terminated by discarding the reagent, followed by washing of the gel slab with 5% acetic acid.
Surgery
Adult C57Black/6 mice of both sexes were used. The animal experiments were approved by the bioethical committee of the KULeuven. All surgical procedures were performed as described previously. 7 For the boost experiment, a group of animals was injected into the right striatum. At 2 months after the first injection, some of the animals received a second injection into the left striatum and were killed 2 months later. At several time points (ie before injection; 2 days, 2 weeks and 2 months after the first injection; 2 weeks and 2 months after the second injection) serum was collected by retro-orbital bleeding.
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Histology
Mice were perfused transcardially with 4% paraformaldehyde in PBS. Coronal brain sections (50 mm thick) were cut with a vibratome. To detect eGFP protein expression, we produced a rabbit polyclonal antibody by immunization with purified eGFP (Clontech, Palo Alto, CA, USA). We also used a monoclonal antibody against NeuN (Chemicon, Temecula, CA, USA). The sections were treated with 3% hydrogen peroxide and preincubated in 5% normal swine serum with 0.1% Triton X-100 in PBS. Incubation with the primary antibody in 5% normal swine serum and 0.1% Triton X-100 was carried out overnight at room temperature. The sections were then incubated in biotinylated swine anti-rabbit secondary antibody, followed by incubation with Strept-ABC-HRP complex (Dako, Glostrup, Denmark). Detection was with diaminobenzidine (DAB) using H 2 O 2 as a substrate.
Quantification of gene expression
The volume of the transduced brain area was quantified by a stereological procedure based on the Cavalieri principle. For each animal, serial sections (minimum six) with an interval of 500 mm centered around the injection site were analyzed by means of a Bioquant image Analysing System (R&M Biometrics, Nashville, TN, USA) connected with a CCD video camera to the microscope. A point-counting grid was placed over the screen upon which the entire transduced brain region was displayed from a low-power objective. Points overlying eGFP-positive cells and fibers were counted. The transduced volume was calculated by multiplying the sum of the counted points with the distance between the counted sections and the area associated with each point on the grid.
Detection of serum antibodies
Before perfusion, a blood sample was taken from the heart of each mouse. Blood sera were analyzed for antibodies directed against the LV preparation by Western blot. Briefly, LV proteins (10 mg) were separated by SDS-PAGE (Novex) and blotted onto a nitrocellulose membrane, followed by incubation with individual mouse sera diluted 1:500. Detection was by subsequent incubation with an HRP-labelled secondary antibody and development with the ECL þ kit (Amersham Pharmacia, Uppsala, Sweden). As a negative control, we used sera from mice collected before injection with LVs. HIV-1-specific bands were identified by comparison with serum from an HIV-1-positive patient. As controls, we also used protein extracts from 293T cells and from the FCS. For some experiments, we transfected 293T cells with 10 mg of the VSV-G envelope plasmid 2 days before making the protein extract. The monoclonal antibody against VSV-G (VSV-G-2.6) was a kind gift from Dr K Thielemans (VU Brussel, Belgium).
Serum neutralization assay
Serum samples were heat inactivated at 561C for 30 min prior to use. Dilutions were made in F12 medium supplemented with 5% FCS, 4 mg/ml polybrene and 20 mg/ml gentamycin. Equal volumes (40 ml) of serially diluted serum and freshly thawed eGFP LVs were incubated for 1 h at 371C and added to CHO-K1 cells (50 000 cells per well plated 24 h before). At 5 h posttransduction, the medium was replaced by F12/5% FCS medium. After 3 days, the cells were trypsinized, fixed with 2% paraformaldehyde and analyzed by FACS for eGFP fluorescence. A standard curve with serial dilutions of untreated eGFP LVs was included in each experiment. The vector dilution corresponding to 40% cell transduction was used. Serum dilutions in the absence of vector served as a control for toxicity. Vector neutralization was calculated at a serum dilution of 1:32 using the formula % neutralization¼((control fluorescenceÀtest fluorescence)/control fluorescence) Â 100.
